|
|
|
No new clinical trials are required, and it is expected that Novartis will be able to respond to all questions fully in 2009. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Journal of the American Medical Association. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book: Course Textbook). (OTC Bulletin Board:AOLS) announced today that data from a study in which AEOL 10150 was administered to 40 mice who had been exposed to radiation show a statistically significant increase in survival rates among mice who were treated with AEOL 10150 compared to controls. Studies funded by the National Institutes for Health are currently underway evaluating AEOL 10150 as a treatment for exposure to mustard gas and will shortly be initiated to evaluate the compound as a treatment for exposure to chlorine gas.
buy where xanax buy xanax online us pharmacy buy xanax with out prescription generic xanax order xanax no prescription
"
About the Novartis Vaccines global meningococcal franchise
Menveo is based on the same proprietary technology Novartis Vaccines pioneered to produce Menjugate, a meningococcal serogroup C conjugate vaccine approved outside the US since 2000 for use in individuals from age 2 months through adulthood. In addition to Menveo, Novartis Vaccines is developing a recombinant vaccine for its potential to provide broad coverage against multiple strains of serogroup B, for which no vaccine is currently available. meningitidis).
For more information, please visit www. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products.
Results to date from this study will be used in the second two parts of the Duke study which will look at dosing, duration of treatment and the maximum length of time after exposure that the drug can be given.
-- Advanced Development Stage – AEOL 10150 has demonstrated safety in three human clinical trials, and has an extensive pre-clinical safety and toxicology package completed.
-- Large scale manufacturing – Aeolus has contract capacity with a large manufacturing site to mass produce large quantities of AEOL 10150 under GMP conditions. Studies will shortly be initiated to further explore AEOL 10150's ability to protect the skin and lungs from damage due to exposure to mustard gas, and to protect the lungs from exposure to chlorine gas. Studies funded by the National Institutes for Health are currently underway evaluating AEOL 10150 as a treatment for exposure to mustard gas and will shortly be initiated to evaluate the compound as a treatment for exposure to chlorine gas.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005